154 related articles for article (PubMed ID: 15557427)
1. EpCAM expression in retinoblastoma: a novel molecular target for therapy.
Krishnakumar S; Mohan A; Mallikarjuna K; Venkatesan N; Biswas J; Shanmugam MP; Ren-Heidenreich L
Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4247-50. PubMed ID: 15557427
[TBL] [Abstract][Full Text] [Related]
2. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress in retinoblastoma: correlations with clinicopathologic features and tumor invasiveness.
Deepa PR; Nalini V; Mallikarjuna K; Vandhana S; Krishnakumar S
Curr Eye Res; 2009 Dec; 34(12):1011-8. PubMed ID: 19958119
[TBL] [Abstract][Full Text] [Related]
4. Histopathological features and P-glycoprotein expression in retinoblastoma.
Filho JP; Correa ZM; Odashiro AN; Coutinho AB; Martins MC; Erwenne CM; Burnier MN
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3478-83. PubMed ID: 16186322
[TBL] [Abstract][Full Text] [Related]
5. The role of nitric oxide synthases and nitrotyrosine in retinoblastoma.
Adithi M; Nalini V; Krishnakumar S
Cancer; 2005 Apr; 103(8):1701-11. PubMed ID: 15754329
[TBL] [Abstract][Full Text] [Related]
6. Nm23 expression in retinoblastoma.
Krishnakumar S; Lakshmi A; Shanmugam MP; Vanitha K; Biswas J
Ocul Immunol Inflamm; 2004 Jun; 12(2):127-35. PubMed ID: 15512982
[TBL] [Abstract][Full Text] [Related]
7. Expression of high mobility group A2 protein in retinoblastoma and its association with clinicopathologic features.
Venkatesan N; Kandalam M; Pasricha G; Sumantran V; Manfioletti G; Ono SJ; Reddy MA; Krishnakumar S
J Pediatr Hematol Oncol; 2009 Mar; 31(3):209-14. PubMed ID: 19262251
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic microRNA 17-92 cluster is regulated by epithelial cell adhesion molecule and could be a potential therapeutic target in retinoblastoma.
Kandalam MM; Beta M; Maheswari UK; Swaminathan S; Krishnakumar S
Mol Vis; 2012; 18():2279-87. PubMed ID: 22969266
[TBL] [Abstract][Full Text] [Related]
9. Retinoblastoma: expression of HLA-G.
Adithi M; Kandalam M; Ramkumar HL; Subramanian A; Venkatesan N; Krishnakumar S
Ocul Immunol Inflamm; 2006 Aug; 14(4):207-13. PubMed ID: 16911982
[TBL] [Abstract][Full Text] [Related]
10. Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
Mu G; Liu H; Zhou F; Xu X; Jiang H; Wang Y; Qu Y
Hum Pathol; 2010 Apr; 41(4):493-502. PubMed ID: 20004941
[TBL] [Abstract][Full Text] [Related]
11. Expression of motility-related protein MRP1/CD9, N-cadherin, E-cadherin, alpha-catenin and beta-catenin in retinoblastoma.
Mohan A; Nalini V; Mallikarjuna K; Jyotirmay B; Krishnakumar S
Exp Eye Res; 2007 Apr; 84(4):781-9. PubMed ID: 17316610
[TBL] [Abstract][Full Text] [Related]
12. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.
Subramanian N; Raghunathan V; Kanwar JR; Kanwar RK; Elchuri SV; Khetan V; Krishnakumar S
Mol Vis; 2012; 18():2783-95. PubMed ID: 23213278
[TBL] [Abstract][Full Text] [Related]
13. Expressions of Rac1, Tiam1 and Cdc42 in retinoblastoma.
Adithi M; Venkatesan N; Kandalam M; Biswas J; Krishnakumar S
Exp Eye Res; 2006 Dec; 83(6):1446-52. PubMed ID: 17027002
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Fas expression in retinoblastoma.
Shanmugam MP; Lakshmi A; Biswas J; Krishnakumar S
Ocul Immunol Inflamm; 2003 Jun; 11(2):107-13. PubMed ID: 14533029
[TBL] [Abstract][Full Text] [Related]
15. Expression of Angiogenic Factors in Invasive Retinoblastoma Tumors Is Associated With Increase in Tumor Cells Expressing Stem Cell Marker Sox2.
Garcia JR; Gombos DS; Prospero CM; Ganapathy A; Penland RL; Chévez-Barrios P
Arch Pathol Lab Med; 2015 Dec; 139(12):1531-8. PubMed ID: 26619025
[TBL] [Abstract][Full Text] [Related]
16. Expression of C-kit in retinoblastoma: a potential therapeutic target.
Barry RJ; de Moura LR; Marshall JC; Fernandes BF; Orellana ME; Antecka E; Martins C; Burnier MN
Br J Ophthalmol; 2007 Nov; 91(11):1532-6. PubMed ID: 17591671
[TBL] [Abstract][Full Text] [Related]
17. Expression of Fas ligand in retinoblastoma.
Krishnakumar S; Kandalam M; Mohan A; Iyer A; Venkatesan N; Biswas J; Shanmugam MP
Cancer; 2004 Oct; 101(7):1672-6. PubMed ID: 15378505
[TBL] [Abstract][Full Text] [Related]
18. Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness.
Camassei FD; Cozza R; Acquaviva A; Jenkner A; Ravà L; Gareri R; Donfrancesco A; Bosman C; Vadalà P; Hadjistilianou T; Boldrini R
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2399-403. PubMed ID: 12766036
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathological correlations of fatty acid synthase expression in retinoblastoma: an Indian cohort study.
Vandhana S; Deepa PR; Jayanthi U; Biswas J; Krishnakumar S
Exp Mol Pathol; 2011 Feb; 90(1):29-37. PubMed ID: 21111730
[TBL] [Abstract][Full Text] [Related]
20. Leucine-Rich α-2-Glycoprotein-1 (LRG-1) Expression in Retinoblastoma.
Amer R; Tiosano L; Pe'er J
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):685-692. PubMed ID: 29392314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
